Company: Gilead Sciences, Inc.
Ticker: GILD
Form: 10-K
Filed: 2026-02-24
Fiscal Period: {"fp": "FY", "fy_curr": 2025, "fy_prev": 2024}

Question: By what percentage did Gilead Sciences, Inc.'s net income change from fiscal year 2024 to fiscal year 2025?
Question Type: temporal_comparison

Concept: NetIncomeLoss
Answer (Numeric): 1672.92
Answer (Display): 1672.92%
Unit: percent_change

Evidence:
[{"chunk_id": "157", "equivalent_chunk_ids": ["157"], "section": "CONSOLIDATED STATEMENTS OF OPERATIONS", "supports": ["current", "previous"], "text": "Year Ended December 31,\n(in millions, except per share amounts)\nRevenues:\nProduct sales\n28,915\n28,610\n26,934\nRoyalty, contract and other revenues\nTotal revenues\n29,443\n28,754\n27,116\nCosts and expenses:\nCost of goods sold\n6,234\n6,251\n6,498\nResearch and development expenses\n5,799\n5,907\n5,718\nAcquired in-process research and development expenses\n1,024\n4,663\n1,155\nIn-process research and development impairments\n4,180\nSelling, general and administrative expenses\n5,774\n6,091\n6,090\nTotal costs and expenses\n19,421\n27,092\n19,511\nOperating income\n10,022\n1,662\n7,605\nInterest expense\n1,024\nOther (income) expense, net\nIncome before income taxes\n9,796\n6,859\nIncome tax expense\n1,286\n1,247\nNet income\n8,510\n5,613\nNet loss attributable to noncontrolling interest\nNet income attributable to Gilead\n8,510\n5,665\nBasic earnings per share attributable to Gilead\n6.84\n0.38\n4.54\nDiluted earnings per share attributable to Gilead\n6.78\n0.38\n4.50\nShares used in basic earnings per share attributable to Gilead calculation\n1,244\n1,247\n1,248\nShares used in diluted earnings per share attributable to Gilead calculation\n1,255\n1,258\nSee accompanying notes.\nGILEAD SCIENCES, INC."}]

Derivation: {"current_value": 8510.0, "op": "pct_change", "previous_value": 480.0}